PITCH DECK

AI Konsultan Cardiovascular Indonesia

Indonesia Healthcare AI Hackathon 2025

CardioCare AI

Smart Cardiovascular Diagnostics with AI

OUR TEAM

RIADI NICO SRI DINI

Problem: Cardiovascular Crisis in Indonesia

Validated data highlighting the urgent need for intervention

#6 Globally

Indonesia ranked 6th worldwide with **375,479 CVD deaths per year**

Source: Global Burden of Disease Study (GBD) 2019, WHO

120% Increase

Prevalence rose from 6.97 million (1990) to **15.34 million cases** (2019)

Source: The 30 Years of Shifting in The Indonesian Cardiovascular Burden (PMC)

29.2%

Adults aged 40+ have **high cardiovascular risk** in Indonesia

Source: SMARThealth Extend study, PLOS One

Indonesia's Cardiovascular Disease Burden

Market Opportunity & Size

Large addressable market with significant growth potential

65M+ Target Users

Indonesians aged 40+ at risk for cardiovascular disease

Source: Indonesian Demographic & Health Data 2023

$778 Million

Indonesia cardiovascular device market projected growth by 2032

Source: Credence Research Market Analysis, 2024

89% Smartphone

Penetration rate across urban and semi-urban Indonesia

Source: Digital Indonesia Report 2023

10,000+ Puskesmas

Indonesia Cardiovascular Market Growth (2024-2032)



Projected market growth from $440.59M (2024) to $778.13M (2032)

Solution: Triple-Layer AI Pipeline

Comprehensive cardiovascular risk assessment powered by medical-grade AI

1. NER Engine

Advanced Named Entity Recognition extracts medical symptoms and cardiovascular terms from patient conversations in Bahasa Indonesia

2. Risk Assessment

Personalized cardiovascular risk scoring using validated AHA/ESC/IHA protocols with Indonesia-specific calibration

3. LLM Chatbot

Contextual, evidence-based responses in Bahasa Indonesia using latest cardiovascular practice guidelines

Medical-Grade Safety Features

- **Zero false-negative:** for emergency cardiovascular conditions (MI, stroke, pulmonary embolism)
- **Always alert:** approach for any potential emergency symptoms with clear guidance
- **Triple-validation:** layer ensures consistent medical advice aligned with cardiovascular guidelines

Unique AI Advantages

- **Domain-specific:** AI focused exclusively on cardiovascular health, not general medicine
- **Bahasa Indonesia native** with local medical terminology and cultural context
- **Evidence-based** responses using AHA/ESC guidelines and Perki (2024) protocols

Product Demo: Smart Cardiovascular Chatbot

AI-powered conversation interface with medical-grade diagnosis capabilities

Smart Symptom Detection

Extracts key cardiovascular symptoms from natural language conversation using specialized Named Entity Recognition (NER) for medical terms in Bahasa Indonesia

Risk Assessment

Calculates personalized risk scores based on AHA/ESC/IHA protocols, identifying high-risk scenarios with zero false-negatives for emergency conditions

Referral System

Provides location-based referrals to nearest healthcare facilities with emergency department capabilities for acute cases

Bahasa Indonesia Native



Medical-grade AI chatbot • Zero false-negative for emergencies • Validated with cardiologists • Indonesia Healthcare AI Hackathon 2025

Key Features & Advantage

Medical-grade cardiovascular AI with unmatched safety and integration

Emergency-Safe: Zero False Negative

Our AI system is designed with patient safety as the highest priority, guaranteeing zero false negatives for acute cardiovascular conditions that require immediate medical attention. Critical symptoms are always flagged for emergency response.

Bahasa Indonesia & Local Context

Optimized for Indonesian language and cultural context, our AI understands local expressions of cardiovascular symptoms and regional health behaviors, making it more accurate and accessible for all Indonesians.

Evidence-Based Medicine

Built on the latest 2024 clinical guidelines from AHA (American Heart Association), ESC (European Society of Cardiology), and PERKI (Indonesian Heart Association) for reliable, up-to-date cardiovascular care.

Triple-Layer AI Architecture

NER → Risk Assessment → LLM

Unmatched accuracy and safety through our proprietary triple-layer AI system for reliable cardiovascular diagnosis.

SATUSEHAT Integration Ready

API-ready for 10,000+ Clinics

Seamless integration with Indonesia's national health system and ready to scale across thousands of healthcare facilities nationwide.

Competitive Landscape

How we compare to existing health solutions in Indonesia

Features	AI Konsultan Cardiovascular	Halodoc	Alodokter	Generic Health Apps
Medical Focus	CVD Specialized	General Health	General Health	General Health
Risk Assessment	✓ Triple-AI Validation	✗	Basic	✗
Medical Protocol	✓ AHA/ESC/Perki 2024	Generic	Generic	✗
Emergency Detection	✓ Zero False-Negative	Limited	Limited	✗
Integration Ready	✓ SATUSEHAT API	✗	✗	✗
AI Model Type	Advanced NER + Risk + LLM	Rule-based	Basic Classification	Simple Questionnaires

Our Key Advantages

Team & Credentials

Our expert team combines AI technology with clinical cardiovascular experience

RIADI MARTA DINATA

AI & Tech Lead

- AI, Computer Vision & IoT specialist
- Medical AI architecture development
- System lead for cardiovascular risk assessment models
- Experience in healthcare AI applications

SRI INDAYATI

Medical Expert & Clinical Advisor

- Licensed nurse with 5+ years clinical experience
- Puskesmas leader with cardiovascular patient care expertise
- Direct patient care for CVD high-risk populations
- Clinical validation and healthcare workflow expert

NICO PURNOMO

Research Assistant

- Medical data collection and analysis
- Survey design and implementation
- TAM analysis for cardiovascular applications
- Research support for AI model development

DINI FITRIANI

Operations Assistant

- AI data support and labeling operations
- User testing and feedback collection
- Implementation logistics for clinical environments
- Community outreach and health education

Business Model & Revenue

Multi-channel strategy with diversified revenue streams

B2G

Government & Healthcare System

- Licensing for Kemenkes/SATUSEHAT integration
- National CVD prevention program API
- Puskesmas deployment program
- **Annual license:** Rp 5M/year

B2B

Clinics & Healthcare Providers

- Private clinics/hospitals SaaS model
- Population health analytics reports
- White-label integration options
- **SaaS pricing:** Rp 250K/month/clinic

B2C

Individual End-Users

- Premium home monitoring features
- Family+ bundle for household coverage
- Personal cardiovascular risk tracking
- **Premium:** Rp 50K/month or Rp 400K/year

Financial Projections (3-Year Outlook)

Metric	Year 1	Year 2	Year 3
Clinics Onboarded	250	1,500	3,000
B2C Users	20,000	130,000	500,000
API Transactions	1.2M	7.5M	18M

Break-even Analysis

Month 18

Break-even point with 750 clinics onboard

Month 24

Profitability milestone

Technical Architecture

Scalable, secure, and medically validated AI pipeline

Cloud AI Backend

- Containerized microservices architecture (AWS/GCP)
- API-ready endpoints for seamless integration
- Multi-region deployment for Indonesia-wide coverage
- HTTPS/TLS encryption with OAuth2 authentication
- Horizontally scalable to handle 10,000+ simultaneous users

Triple-Layer AI Pipeline

- NER Layer: Bahasa Indonesia medical entity extraction (90%+ precision)
- Risk Engine: Cardiovascular risk calculation using validated AHA/ESC protocols
- LLM Layer: Fine-tuned medical chatbot with domain-specific knowledge
- Zero false-negative emergency detection with multi-pass verification

AI Konsultan Cardiovascular Technical Flow



Implementation Roadmap

Phased deployment from hackathon MVP to national rollout

Hackathon MVP — 48 hours

Clinical Validation — Month 1-3

Field Pilot — Month 4-6

Product Scale — Month 7-12

National Launch — Month 13+

</> Hackathon (48h)

- Working MVP bot with core functionality
- AI risk engine with medical validation
- Demo dataset with 200+ test cases
- Basic API endpoints established
- Clinical expert review protocol

Clinical Testing (M1-3)

- Initial deployment in 2 clinics
- 500+ patient data collection
- Medical expert validation of outputs
- Safety protocol development
- Feature refinement based on feedback

Scale & Launch (M4-13+)

- M4-6: Field pilot with 20 clinics, 2K patients
- M7-12: Product scale, API onboarding
- M7-12: Regulatory audit & compliance
- M13+: National launch across Indonesia
- M13+: SATUSEHAT integration complete

48 Hours

2 Clinics

M6

M18

Financial Projections

Revenue growth, break-even analysis, and profitability metrics

Year 1

250 clinics, Rp 13,5M

- 20,000 users onboarded
- Initial API partnerships
- Focus on user acquisition

Year 2

1,500 clinics, Rp 23M

- 130,000 active users
- Expanded hospital integrations
- Break-even achieved in Month 18

Year 3

3,000 clinics, Rp 35M

- 500,000 users nationwide



Month 1	Month 18	Month 24	Month 36
Launch	Break-Even	Profitable	Rp 35M Revenue

Impact Metrics

Measurable outcomes and healthcare system transformation

500,000+ Lives

Direct impact on **half a million Indonesians** within the first 3 years of implementation

Based on cardiovascular patient distribution across target regions

15% Reduction

CVD mortality reduction target through early detection and timely intervention

Aligned with World Health Organization CVD reduction goals

Rp 10+ Trillion

Healthcare cost savings through prevention and early intervention

Based on average cost of emergency cardiovascular care and hospitalizations

Projected Impact Over 3 Years



Progressive increase in lives impacted and early detection rates across implementation phases

Risk Assessment & Mitigation

Comprehensive strategy addressing clinical, technical, regulatory, and market risks

Clinical Risk

Risk: False negatives in emergency cardiovascular situations could lead to delayed interventions and adverse outcomes.

- Triple-layer AI validation ensures emergency cases are flagged with zero false-negatives
- Clear emergency protocol with automatic alerts for high-risk symptoms
- Regular clinical validation against AHA/ESC/Perki 2024 guidelines

Data Privacy

Risk: Patient health data requires strict protection to ensure privacy and compliance with health information regulations.

- On-premise/In-Indonesia server deployment compliant with local data sovereignty laws
- End-to-end encryption for all patient communication
- Anonymized data pipeline for aggregated insights with opt-in consent

Regulatory Compliance

Risk: Healthcare AI solutions require regulatory approval before widespread clinical deployment.

- Early engagement with Kemenkes and Perki regulatory experts
- SATUSEHAT API integration pathway already mapped
- Clinical trial design aligns with Indonesian medical device regulations

Market Challenges

Risk: Adoption barriers with healthcare providers and competition from established players.

- Phased rollout strategy starting with early-adopter clinics
- Cardiovascular-specific focus differentiates from general health apps
- Partner network leverages existing healthcare infrastructure

Regulatory & SATUSEHAT Pathway

Ready for healthcare system integration and regulatory compliance

Kemenkes Alignment

Integration pathway aligned with Ministry of Health (Kemenkes) digital health guidelines

Compliant with Indonesia's health data sovereignty requirements

Ready for Sistem Informasi Manajemen Kesehatan integration

IHA/Perki Protocols

Implementing Indonesian Heart Association (Perki) CVD management guidelines

Algorithm aligned with AHA, ESC, and Perki 2024 revisions

Clinical workflow validation through Perki advisory network

Clinical Trial Readiness

Study protocol prepared for IRB submission



Integration & Compliance Ready

Data Privacy Compliant

Medical Device Registration Path

SATUSEHAT API Ready

Clinical Trial Protocol

Investment & Funding Request

Seeking Rp 15M Seed Funding

Model Development & Labeling

Survey, data collection, medical annotation, clinical research

Rp 3,000,000

Operational API & Infrastructure

$20/month/core for Year 1, hosting, database, security

Rp 3,600,000

Regulatory & Clinical Trials

Kemenkes compliance, medical validation, SATUSEHAT integration

Rp 4,500,000

Go-to-Market & Pilot Programs

Marketing, clinic partnerships, user acquisition, Puskesmas pilots

Rp 3,900,000

18-Month Runway

Months 1-3: MVP refinement, initial clinical validation

Months 4-8: Regulatory approval, first 20 clinic partnerships

Months 9-12: Market penetration, API integration

Months 13-18: Scaling to 750+ clinics, break-even point

Return on Investment

Break-even: Month 18

Profitable: Month 24

500,000+ lives impacted by Year 3

15% target reduction in CVD mortality

Detailed financial projections and budget allocation plan available upon request

Call to Action & Contact

Ready for Hackathon & National Scale

Our AI Konsultan Cardiovascular Indonesia solution is prepared for immediate implementation with:

- Working MVP - Functional AI cardiovascular risk assessment
- Clinical Validation - Healthcare professional oversight
- Scalable System - Ready for national deployment
- SATUSEHAT Ready - Compliant with national health infrastructure
- Evidence-Based - Built on latest AHA/ESC/Perki 2024 protocols

Partner With Us Today

AI Konsultan Cardiovascular Indonesia

Advanced AI solution for cardiovascular risk assessment and guidance

Riadi Marta Dinata

AI & Tech Lead (AI, Computer Vision, IoT)

Ners DAYAN HISNI S.Kep, M.N.S

Senior Nurse (5+ years cardiovascular experience)

BBB & CCC

Research & Operations Support

Email

adiarray@istn.ac.id

Demo Available

Scan QR code or contact us for live demo access

"Transforming cardiovascular care in Indonesia through accessible AI technology"

REFERENCES

Ready for healthcare system integration and regulatory compliance

- Krittanawong, C., et al. (2024). Transforming Cardiovascular Care With Artificial Intelligence: From Discovery to Practice: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 84(1), 97-114. doi: 10.1016/j.jacc.2024.05.003
- Sallam, M., et al. (2024). Advancements and applications of Artificial Intelligence in cardiology: Current trends and future prospects. Clinical and Translational Discovery, 4(3), e628. doi: 10.1016/S2949-916X(24)00062-8
- Krumholz, H. M., et al. (2024). Use of Artificial Intelligence in Improving Outcomes in Heart Disease: A Scientific Statement From the American Heart Association. Circulation, 149(14), e1028-e1050. doi: 10.1161/CIR.0000000000001201
- Zhang, J., et al. (2024). Artificial intelligence applied in cardiovascular disease: a bibliometric and visual analysis. Frontiers in Cardiovascular Medicine, 11, 1323918. doi: 10.3389/fcvm.2024.1323918
- Muharram, F. R., et al. (2024). The 30 Years of Shifting in The Indonesian Cardiovascular Burden—Analysis of The Global Burden of Disease Study. Journal of Epidemiology and Global Health, 14(3), 1184-1200. doi: 10.1007/s44197-024-00187-8
- Al-Zaiti, S. S., et al. (2024). Artificial Intelligence for Cardiovascular Care—Part 1: Advances: JACC Review Topic of the Week. Journal of the American College of Cardiology, 83(25), 2418-2430. doi: 10.1016/j.jacc.2024.03.400
- Sun, X., et al. (2023). Artificial intelligence in cardiovascular diseases: diagnostic and therapeutic perspectives. European Journal of Medical Research, 28, 242. doi: 10.1186/s40001-023-01065-y
- Liu, S., et al. (2024). Evaluating Medical Entity Recognition in Health Care: Entity Model Quantitative Study. JMIR Medical Informatics, 12, e59782. doi: 10.2196/59782
- Martinez-Rodriguez, C., et al. (2023). Named Entity Recognition in Electronic Health Records: A Methodological Review. Healthcare Informatics Research, 29(4), 324-336. doi: 10.4258/hir.2023.29.4.324
- Ahmad, P. N., et al. (2023). A Review on Electronic Health Record Text-Mining for Biomedical Name Entity Recognition in Healthcare Domain. Healthcare, 11(9), 1268. doi: 10.3390/healthcare11091268
- Chen, H., et al. (2024). An improved data augmentation approach and its application in medical named entity recognition. BMC Medical Informatics and Decision Making, 24, 221. doi: 10.1186/s12911-024-02624-x
- Li, F., et al. (2022). Named entity recognition of Chinese electronic medical records based on a hybrid neural network and medical MC-BERT. BMC Medical Informatics and Decision Making, 22, 354. doi: 10.1186/s12911-022-02059-2
- Šuvalov, H., et al. (2025). Using Synthetic Health Care Data to Leverage Large Language Models for Named Entity Recognition: Development and Validation Study. Journal of Medical Internet Research, 27(1), e66279. doi: 10.2196/66279
- Lee, J., et al. (2019). Ontology-Based Healthcare Named Entity Recognition from Twitter Messages Using a Recurrent Neural Network Approach. International Journal of Environmental Research and Public Health, 16(19), 3628. doi: 10.3390/ijerph16193628